All In Biotech

Drug Trial Radar · NCT06794996

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 4, 2025

Primary completion

Jul 20, 2026

Study completion Jul 20, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 67 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).

Conditions

  • Proteinuric Kidney Disease

Interventions

  • InaxaplinDrug

    Tablets for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Urine Albumin-Creatinine Ratio (UACR)Time frame: Baseline and At Week 13

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Nephrology Consultants, LLC

    Huntsville, Alabama

  • Foundation for Sickle Cell Disease Research, LLC

    Hollywood, Florida

  • South Florida Research Institute

    Lauderdale Lakes, Florida

  • Schiff Center for Liver Diseases

    Miami, Florida

  • CTR Oakwater, LLC

    Orlando, Florida

  • Renal Associates, LLC

    Columbus, Georgia

  • Georgia Nephrology - Decatur

    Decatur, Georgia

  • Javara Inc./Privia Medical Group Georgia, LLC - Fayetteville

    Fayetteville, Georgia

  • Georgia Nephrology

    Lawrenceville, Georgia

  • Javara Inc. /Privia Medical Group Georgia, LLC - Savannah

    Savannah, Georgia

  • Renal Associates of Baton Rouge

    Baton Rouge, Louisiana

  • LCMC Health

    Metairie, Louisiana

  • Ochsner Medical Center - New Orleans - Nephrology

    New Orleans, Louisiana

  • Northwest Louisiana Nephrology, LLC - Shreveport

    Shreveport, Louisiana

  • Javara Inc./Privia Medical Group, LLC MidAtlantic-Silver Spring, MD

    Silver Spring, Maryland

  • Nephrology Associates, P.C.

    Columbus, Mississippi

  • Nephrology and Hypertension Associates, LTD

    Tupelo, Mississippi

  • DaVita Kidney Care - Las Vegas

    Las Vegas, Nevada

  • Saint Michael's Medical Center - Peter Ho Memorial Clinic

    Newark, New Jersey

  • Rutgers Doctors Office Center

    Newark, New Jersey

  • Scott Research, Inc.

    Laurelton, New York

  • NYC Health + Hospital/Harlem

    New York, New York

  • North Carolina Nephrology P.A. - Cary Office

    Cary, North Carolina

  • UNC Clinical and Translational Research Center

    Chapel Hill, North Carolina

  • Duke University Hospital - Children's Health Center

    Durham, North Carolina

  • Eastern Nephrology Associates - New Bern Office

    New Bern, North Carolina

  • Lewis Katz School of Medicine at Temple University - Section of Nephrology

    Philadelphia, Pennsylvania

  • Columbia Nephrology Associates, PA

    Columbia, South Carolina

  • Carolina Nephrology, PA

    Spartanburg, South Carolina

  • Dallas Renal Group - 2

    Dallas, Texas

  • Dallas Renal Group - 1

    Dallas, Texas

  • Dallas Nephrology Associates - Dallas Landry Office

    Dallas, Texas

  • UTSW Medical Center - Nephrology

    Dallas, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Tks Research, P.L.L.C.

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.